Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.
Zainabadi K, Walsh KF, Vilbrun SC, Mathurin LD, Lee MH, Saito K, Mishra S, Ocheretina O, Pape JW, Nathan C, Fitzgerald DW. Zainabadi K, et al. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0060821. doi: 10.1128/AAC.00608-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34060896 Free PMC article.
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.
Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K, Brown CD, Hsu J, Kyriakides C, Chiu S, Cappelli LV, Cacciapuoti MT, Tam W, Galluzzi L, Simonson PD, Elemento O, Salvatore M, Inghirami G. Rendeiro AF, et al. Life Sci Alliance. 2020 Dec 24;4(2):e202000955. doi: 10.26508/lsa.202000955. Print 2021 Feb. Life Sci Alliance. 2020. PMID: 33361110 Free PMC article.
Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.
Rendeiro AF, Casano J, Kyriakos Vorkas C, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K, Brown CD, Hsu J, Kyriakides C, Chiu S, Cappelli L, Teresa Cacciapuoti M, Tam W, Galluzzi L, Simonson PD, Elemento O, Salvatore M, Inghirami G. Rendeiro AF, et al. medRxiv [Preprint]. 2020 Sep 9:2020.09.08.20189092. doi: 10.1101/2020.09.08.20189092. medRxiv. 2020. PMID: 32935114 Free PMC article. Updated. Preprint.
Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.
Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Jean Francois D, Zimmerman M, Kaya F, Zhang N, Saito K, Ocheretina O, Savic R, Dartois V, Johnson WD, Pape JW, Nathan C, Fitzgerald DW. Walsh KF, et al. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e01956-19. doi: 10.1128/AAC.01956-19. Print 2020 Apr 21. Antimicrob Agents Chemother. 2020. PMID: 32071052 Free PMC article. Clinical Trial.